Factors influencing treatment response and outcome of first-episode schizophrenia: Implications for understanding the pathophysiology of schizophrenia

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 9, 1996, Pages 5-9

  Lieberman, Jeffrey A ^a,b   Koreen, Amy R ^a   Chakos, Miranda ^a   Sheitman, Brian ^a   Woerner, Margaret ^a   Alvir, Jose Ma J ^a   Bilder, Robert ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

BEHAVIOR DISORDER; CONFERENCE PAPER; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MORBIDITY; ONSET AGE; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSIS; RECURRENT DISEASE; SCHIZOPHRENIA; SEX DIFFERENCE; TARDIVE DYSKINESIA;

ADULT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; BRAIN; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; PROGNOSIS; RECURRENCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; SOCIAL ADJUSTMENT; TREATMENT OUTCOME;

EID: 0029797948     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (43)

1. McGlashan TH, A selective review of recent North American long-term follow-up studies of schizophrenia. Schizophr Bull 1988;14(4):515-542
2. Lieberman JA, Kinon BJ, Loebel AD. Dopaminergic mechanisms of idiopathic and drug induced psychosis. Schizophr Bull 1990;16(1):97-110
3. Carpenter WT, Buchanan RW. Domains of psychopathology relevant to the study of etiology and treatment of schizophrenia. In: Schultz SC, Tamminga CT, eds. Schizophrenia: Scientific Progress. New York, NY: Oxford University Press; 1989
4. McGlashan TH, Fenton WS. Classical subtypes for schizophrenia: literature review for DSM-IV. Schizophr Bull 1991;17:609-632
5. Chouinard G, Jones B. Neuroleptic induced supersensitivity psychosis. Am J Psychiatry 1980;137:16-21
6. Davis K, Rosenberg G. Is there a limbic system equivalent of tardive dyskinesia? Biol Psychiatry 1979;14:699-703
7. Chakos MH, Alvir JMJ, Woerner MG, et al. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch Gen Psychiatry. In press
8. Lieberman JA, Alvir J, Geisler S, et al. Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia. Neuropsychopharmacology 1994;11(2):107-118
9. Chakos MH, Lieberman JA, Bilder RM, et al. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. Am J Psychiatry 1994;151:1430-1436
10. Chakos MH, Lieberman JA, Alvir J, et al. Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine [letter]. Lancet 1995;345:456
11. Keshavan MS, Bagwell WW, Haas GL, et al. Changes in caudate volume with neuroleptic treatment [letter]. Lancet 1994;344:1434
12. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991;17:325-351
13. Wyatt RJ. Early intervention for schizophrenia: can the course of the illness be altered? Biol Psychiatry 1995;38(1):1-3
14. May PR, Tuma AH, Dixon WJ. Schizophrenia: a follow-up study of the results of the five forms of treatment. Arch Gen Psychiatry 1991;38:776-784
15. Crow TJ, MacMillan JF, Johnson AL, et al. A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 1986;428:120-127
16. Loebel AD, Lieberman JA, Alvir JMJ, et al. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992;149:1183-1188
17. Pfohl B, Winokur G. The micropsychopathology of hebephrenic/catatonic schizophrenia. J Nerv Ment Dis 1983;171(5):296-300
18. Carpenter WT, Heinrichs DW, Wagman AMI. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 1988;145:578-583
19. Mayerhoff DI, Loebel AD, Borenstein M, et al. The deficit state in first-episode schizophrenia. Am J Psychiatry 1994;151:1417-1422
20. Levinson DF, Simpson GM, Singh H, et al. Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. Arch Gen Psychiatry 1990;47:761-768
21. Kinon BJ, Kane JM, Chakos M, et al. Possible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects. Psychopharmacol Bull 1993;29(3):365-369
22. Chakos MH, Mayerhoff DI, Loebel AD, et al. Incidence and correlates of acute extrapyramidal symptoms in first episode schizophrenia. Psychopharmacol Bull 1992;28(1):81-86
23. Chatterjee A, Chakos M, Koreen A, et al. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesias in never medicated schizophrenic patients. Am J Psychiatry 1995;152:1724-1729
24. Amin F, Davidson M, Davis KL. Homovanillic acid measurement in clinical research: a review of methodology. Schizophr Bull 1991;18:123-148
25. Koreen AR, Lieberman J, Alvir J, et al. Plasma homovanillic acid levels in first-episode schizophrenia: psychopathology and treatment response. Arch Gen Psychiatry 1994;51:132-138
26. Chakos M, Alvir J, Koreen A, et al. Incidence and correlation of acute extrapyramidal symptoms in first episode schizophrenia. Presented at the 50th Annual Meeting of the Society of Biological Psychiatry; May 17-21, 1995; Miami, Fla
27. Akiyama K, Tsuchida K, Kanzaki A, et al. Plasma homovanillic acid levels and therapeutic outcome in schizophrenics comparison of neuroleptic naive first episode patients and patients with disease exacerbation due to neuroleptic discontinuance. Biol Psychiatry 1995;38(10):639-648
28. Bogerts B, Lieberman JA, Ashtari M, et al. Hippocampus-amygdala volumes and psychopathology in chronic schizophrenia. Biol Psychiatry 1993;33:236-246
29. Bogerts B, Ashtari M, Degreef G, et al. Reduced temporal limbic structure volumes on magnetic resonance images in first-episode schizophrenia. Psychiatry Res 1990;35:1-13
30. Lieberman J, Bogerts B, Degreef G, et al. Qualitative assessment of brain morphology in acute and chronic schizophrenia. Am J Psychiatry 1992; 149:784-794
31. Lieberman J, Jody D, Geisler S, et al. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 1993;50:369-376
32. Waddington JL, Lieberman JA. New insights into clinical issues in schizophrenia. Journal of Psychopharmacology 1994;8:65-66
33. DeLisi LE, Hoff AL, Kushner M, et al. Left ventricular enlargement associated with diagnostic outcome of schizophreniform disorder. Biol Psychiatry 1992;32(2):199-201
34. Cole JO, Goldberg SC, Klerman GL. Phenothiazine treatment in acute schizophrenia. Arch Gen Psychiatry 1964;10:246-261
35. Cole JO, Goldberg SC, Davis JM. Drugs in the treatment of psychosis: controlled studies. In: Solomon P, ed. Psychiatric Drugs. New York, NY: Grune & Stratton; 1966:153-180
36. McEvoy JP, Hogarty GE, Steingar S. Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 1991;48:739-745
37. Van Putten T, Marder SR, Mintz J. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry 1990;47:754-758
38. Volavka J, Cooper T, Czobor P, et al. Haloperidol blood levels and clinical effects. Arch Gen Psychiatry 1992;49:354-361
39. Rifkin A, Doddi S, Karajgi B, et al. Dosage of haloperidol for schizophrenia. Arch Gen Psychiatry 1991;48:166-170
40. Levinson DF, Simpson GM, Singh H, et al. Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. Arch Gen Psychiatry 1990;47:761-768
41. Lieberman J, Borenstein M. Clinical response of first episode schizophrenic patients to maintenance medication and family treatment. Presented at the American College of Neuropsychopharmacology Annual Meeting; December 14-18, 1992; San Juan, Puerto Rico
42. Lieberman J, Alvir J, Woerner M, et al. Prospective study of psychobiology in first episode schizophrenia at Hillside Hospital: design, methodology and summary of findings. Schizophr Bull 1992;18:351-371
43. Lieberman JA, Jody D, Alvir JMJ, et al. Brain morphology, dopamine and eye-tracking abnormalities in first-episode schizophrenia: prevalence and clinical correlates. Arch Gen Psychiatry 1993;50:357-368